Fate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered Master Pluripotent Cell Line
Tweet Send to a Friend
Fate Therapeutics, Inc. (NASDAQ: FATE) announced today the generation of chimeric antigen receptor (CAR)-targeted CD8αβ+ T cells from a clonal ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
